Evidence map›Paper›PMID 32337506›Full record

ReviewVaccine: X2020

Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile.

Thomas P Monath, Jeroen Kortekaas, Douglas M Watts, Rebecca C Christofferson, Angelle Desiree LaBeaud, Brian Gowen, Clarence J Peters, Darci R Smith, Robert Swanepoel, John C Morrill and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccine: X, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.1field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Replication Kinetics of a Candidate Live-Attenuated Vaccine for Cache Valley Virus inVector borne and zoonotic diseases (Larchmont, N.Y.) · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 2 countries.

Thomas P MonathManaging Partner and Chief Scientific Officer, Crozet BioPharma LLC, Devens, MA, USA.
Jeroen KortekaasProfessor of Veterinary Arbovirology, Department of Virology, Wageningen Bioveterinary Research, Lelystad, the Netherlands.
Douglas M WattsExecutive Director of Vet Services, and Director of Biosafety Level 3 Laboratory and Co-Director of BBRC Infectious Disease and Immunology, University of Texas at El Paso, El Paso, TX, USA.
Rebecca C ChristoffersonPathobiological Sciences, Louisiana State University, School of Veterinary Medicine, Baton Rouge, LA, USA.
Angelle Desiree LaBeaudProfessor of Pediatrics (Infectious Diseases), Stanford University School of Medicine, Senior Fellow at the Woods Institute for the Environment and Professor of Health Research and Policy (Epidemiology) at the Lucile Salter Packard Children's Hospital, Stanford, CA, USA.
Brian GowenUtah State University, Logan, UT, USA.
Clarence J PetersProfessor (Emeritus) Departments of Microbiology & Immunology and Pathology Director (Emeritus) for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
Darci R SmithImmunodiagnostics Department, Naval Medical Research Center, Biological Defense Research Directorate, Fort Detrick, MD, USA.
Robert SwanepoelDepartment of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, Gauteng, South Africa.
John C MorrillDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Thomas G KsiazekDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Phillip R PittmanU.S. Army Medical Research Institute of Infectious Diseases, Medical Research and Materiel Command, Fort Detrick, Frederick, MD, USA.
Brian H BirdViral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
George BettingerUSAID Rift Valley Fever Vaccine Project at The University of Texas at El Paso, El Paso, TX, USA.
The University of Texas Medical Branch at Galveston · USCenters for Disease Control and Prevention · USThe University of Texas at El Paso · USCrozet BioPharma (United States) · USLouisiana State University · USNaval Medical Research Command · USOnderstepoort Veterinary Academic Hospital · ZAStanford University · USUnited States Army Medical Research Institute of Infectious Diseases · USUtah State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In November 2019, The World Health Organization (WHO) issued a draft set of Target Product Profiles (TPPs) describing optimal and minimally acceptable targets for vaccines against Rift Valley fever (RVF), a Phlebovirus with a three segmented genome, in both humans and ruminants. The TPPs contained rigid requirements to protect against genomic reassortment of live, attenuated vaccines (LAVs) with wild-type RVF virus (RVFV), which place undue constraints on development and regulatory approval of LAVs. We review the current LAVs in use and in development, and conclude that there is no evidence that reassortment between LAVs and wild-type RVFV has occurred during field use, that such a reassortment event if it occurred would have no untoward consequence, and that the TPPs should be revised to provide a more balanced assessment of the benefits versus the theoretical risks of reassortment.

Indexed as

Genetic reassortmentRift Valley Fever vaccineTarget Product Profile

Identifiers

PMID32337506
PMCPMC7176985
OpenAlexW3016054334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.